Maghak Lauren, Larsen Jessica
ACS Biomater Sci Eng. 2020 Sep 14;6(9):4846-4850. doi: 10.1021/acsbiomaterials.0c00680. Epub 2020 Jul 22.
Polyethylene glycol--polylactic acid (PEG-PLA) and polyethylene glycol--poly(lactic--glycolic) acid) (PEG-PLGA) are two copolymers made up of three currently FDA approved polymers, used as drug delivery systems for specific indications. Here, the two were investigated to determine how they affected individual blood components and how they affected whole blood. Transmission and scanning electron microscopy imaging for each blood component and whole blood was completed with each amphiphilic copolymer for comparison. It was found that PEG-PLA does not disturb whole blood or its components, but PEG-PLGA harms platelets and plasma. These findings regarding PEG-PLGA show that this material is not compliant with all current FDA standards and could explain why clinical trials are facing complications.
聚乙二醇-聚乳酸(PEG-PLA)和聚乙二醇-聚(乳酸-乙醇酸)(PEG-PLGA)是由三种目前已获美国食品药品监督管理局(FDA)批准的聚合物组成的两种共聚物,用作特定适应症的药物递送系统。在此,对这两种共聚物进行了研究,以确定它们如何影响个体血液成分以及如何影响全血。使用每种两亲共聚物对每种血液成分和全血进行了透射和扫描电子显微镜成像,以便进行比较。结果发现,PEG-PLA不会干扰全血或其成分,但PEG-PLGA会损害血小板和血浆。这些关于PEG-PLGA的发现表明,这种材料不符合目前所有的FDA标准,这可以解释为什么临床试验会面临并发症。